Advanced Systemic Mastocytosis Markedly Raises Five Year Mortality Advanced systemic mastocytosis (SM) increased 5-year mortality more than 11-fold compared to reference cohorts.

Advanced systemic mastocytosis (#AdvSM) was associated with a markedly elevated risk of death over 5 years compared with well-matched reference cohorts, and even nonadvanced disease conferred excess mortality.

Read here: https://bit.ly/4aZs0ym

#RareDisease #SystemicMastocytosis

Avapritinib Delivers Durable Survival Gains in Advanced Systemic Mastocytosis Avapritinib produced deep, durable responses in advanced systemic mastocytosis (SM) with a 73% ORR and median OS of 62 months at 4 years.

#Avapritinib produced deep and durable clinical benefit with prolonged survival in patients with #AdvSM, with low rates of disease progression over more than 4 years of follow-up and a favorable benefit-risk profile. @bloodadvances.bsky.social

Read here: https://bit.ly/4tAWezk